OncoMatch/Clinical Trials/NCT05579366
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Is NCT05579366 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Rina-S and Carboplatin for high grade epithelial ovarian cancer.
Treatment: Rina-S · Carboplatin · Bevacizumab · Pembrolizumab — This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Endometrial Cancer
Non-Small Cell Lung Carcinoma
Mesothelioma
Breast Carcinoma
Triple-Negative Breast Cancer
Biomarker criteria
Required: EGFR mutation
EGFR-mutated NSCLC (Part B)
Allowed: BRCA1 deleterious germline or somatic mutation
Participants with known or suspected deleterious germline or somatic BRCA mutations (as determined by Food and Drug Administration [FDA]-approved test in a Clinical Laboratory Improvement Amendments [CLIA]-certified laboratory; or locally approved equivalent) and who achieved a complete or partial response to platinum-based chemotherapy must have been treated with a poly ADP-ribose polymerase (PARP) inhibitor as maintenance treatment.
Allowed: BRCA2 deleterious germline or somatic mutation
Participants with known or suspected deleterious germline or somatic BRCA mutations (as determined by Food and Drug Administration [FDA]-approved test in a Clinical Laboratory Improvement Amendments [CLIA]-certified laboratory; or locally approved equivalent) and who achieved a complete or partial response to platinum-based chemotherapy must have been treated with a poly ADP-ribose polymerase (PARP) inhibitor as maintenance treatment.
Disease stage
Metastatic disease required
Prior therapy
Must have received: platinum-based chemotherapy
Participants must have received prior platinum-based chemotherapy
Must have received: bevacizumab or approved biosimilar
Participants must have received prior bevacizumab or approved biosimilar
Must have received: PARP inhibitor — maintenance
must have been treated with a poly ADP-ribose polymerase (PARP) inhibitor as maintenance treatment
Must have received: programmed death-ligand 1 (PD-L1) inhibitor
Participants must have received ... a programmed death-ligand 1 (PD-[L])1 inhibitor
Cannot have received: topoisomerase 1 inhibitor-based antibody drug conjugate
Prior therapy with a topoisomerase 1 inhibitor-based antibody drug conjugate
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- USOR HonorHealth · Phoenix, Arizona
- USOR Arizona Oncology Associates · Tucson, Arizona
- University of California Los Angeles Medical Center · Los Angeles, California
- University of California, San Diego; Moores Cancer Center · San Diego, California
- USOR Sansum Clinic · Santa Barbara, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify